<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105710">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01672762</url>
  </required_header>
  <id_info>
    <org_study_id>1941-CL-0122</org_study_id>
    <nct_id>NCT01672762</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients</brief_title>
  <official_title>Phase 3 Study of ASP1941 - A Long-term Administration Study in Subjects With Type 2 Diabetes Mellitus (T2DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate safety and efficacy of ASP1941 after 24 week administration to
      diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will undergo the 6-week screening period before entering the 24-week treatment
      period and will receive ASP1941 before breakfast during the treatment period.  All subjects
      will be followed for 4 weeks after study treatment is discontinued.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Before and at 4-, 8-, 12-, 16-, 20- and 24-week</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose</measure>
    <time_frame>Before and at 4-, 8-, 12-, 16-, 20- and 24-week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum insulin</measure>
    <time_frame>Before and at 4-, 8-, 12-, 16-, 20- and 24-week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Before and at 4-, 8-, 12-, 16-, 20- and 24-week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Before and at 4-, 8-, 12-, 16-, 20- and 24-week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine glucose</measure>
    <time_frame>Before and at 4-, 8-, 12-, 16-, 20- and 24-week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs, lab-tests and 12-lead ECGs</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>ASP1941 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1941</intervention_name>
    <description>oral</description>
    <arm_group_label>ASP1941 group</arm_group_label>
    <other_name>ipragliflozin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus patients

          -  Subject is only on a diet and exercise program or has received a single
             antihyperglycemic agent or two antihyperglycemic agents (excluding insulin) with low
             dose (≤50% of the maximum dose of each recommended dosage)

          -  Subject has a HbA1c value (JDS value) between 6.5% and 9.5% and the difference of
             HbA1c values (JDS value) within ± 1.0%

          -  BMI 20.0 - 45.0 kg/m2

        Exclusion Criteria:

          -  Type 1 Diabetes Mellitus

          -  Subject has received insulin within 12 weeks (84 days) before the study

          -  Subject has proliferative diabetic retinopathy

          -  Subject has a history of clinically significant renal disease such as renovascular
             occlusive disease, nephrectomy and/or renal transplant

          -  Subject with obvious dysuria caused by a neurogenic bladder or a benign prostatic
             hypertrophy

          -  Subject has a history of cerebral vascular attack, unstable angina, myocardial
             infarction, vascular intervention, and heart disease (NYHA Class III-IV) within 12
             weeks (84 days).  Subject has heart disease, cerebral vascular disease which, in the
             opinion of the principal investigator or the sub-investigator, may interfere with
             treatment or evaluation of safety of this study.

          -  Female subject who is currently pregnant or lactating, or who is possibly pregnant

          -  Male and pre-menopausal Female subject who cannot use an appropriate contraception
             during the study

          -  Subject has a history of treatment with ASP1941

          -  Subject has participated in another clinical study, post marketing study, or medical
             equipment study within 12 weeks (84 days) before providing written informed consent,
             or who is currently participating in any of those studies

          -  Subject has a serum creatinine value higher than upper limit of normal range

          -  Subject has a urinary microalbumin/ urinary creatinine ratio &gt; 300 mg/g in urinalysis

          -  Subject has uncontrolled severe hypertension (subject whose systolic blood pressure
             is &gt; 170 mmHg or diastolic blood pressure of &gt; 95 mmHg measured in a sitting position
             after 5 minutes of rest

          -  Subject who is judged inappropriate for enrollment into the study by the principal
             investigator or the sub-investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Touhoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 23, 2013</lastchanged_date>
  <firstreceived_date>August 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>serum Insulin</keyword>
  <keyword>blood glucose</keyword>
  <keyword>glucose excretion</keyword>
  <keyword>hypoglycemic agents</keyword>
  <keyword>ipragliflozin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
